术者及医院手术量对非转移性前列腺癌根治术后肿瘤学与非肿瘤学结局影响的系统综述
结果显示手术量增加与死亡率、切缘阳性率、辅助或挽救治疗率及围术期并发症率降低相关,医院年手术量阈值中位数为86例(IQR 35-100),超过该阈值后手术量越高结局越好,尤其切缘阳性率。
要点
- 术者及医院手术量增加与根治性前列腺切除术后切缘阳性率、辅助或挽救治疗率及围术期并发症率降低相关。
- 医院年手术量阈值中位数为86例(IQR 35-100),超过该阈值后手术量越高结局越好。
- 低手术量中心术者仍可能达到相似甚至更好结局,应公开结局数据促进知情决策。
核心结论
- 根治性前列腺切除术的术者及医院手术量越高,切缘阳性率、辅助或挽救治疗率及围术期并发症率越低。
- 该关联从年手术量超过86例(IQR 35-100)开始显现,此后可能进一步改善。
研究设计与样本
- 系统综述,检索Medline、Medline In-Process、Embase和Cochrane Central Register of Controlled Trials。
- 主要结局包括肿瘤学结局(前列腺特异性抗原持续存在、切缘阳性、生化复发、局部和远处复发、肿瘤特异性和总生存)和非肿瘤学结局(围术期并发症包括输血需求、中转开放手术和90天内死亡,以及控尿和勃起功能)。
- 进行了偏倚风险和混杂评估,计划在数据允许时进行叙述性和定量合成。
主要发现
- 总体而言,术者和医院手术量增加与死亡率、切缘阳性率、辅助或挽救治疗率及围术期并发症率降低相关。
- 合并纳入研究使用的组大小截断值,结局开始出现差异的医院手术量阈值中位数为每年86例(IQR 35-100)。
- 超过该阈值后,手术量越高结局越好,尤其对切缘阳性率。
- 大多数领域的偏倚风险和混杂风险高。
关键数值与推荐
- 医院年手术量阈值中位数为86例(IQR 35-100),超过该阈值后手术量越高结局越好。
- 大多数领域的偏倚风险和混杂风险高。
临床怎么用
- 高手术量和低手术量中心均应测量其结局并公开,必要时改进医疗质量。
- 应国际推广公开医院结局数据,使患者能够在知情情况下决定治疗地点。
- 低手术量医院工作的术者仍可能达到相似甚至更好结局。
局限性
- 纳入研究均为回顾性比较研究。
- 大多数领域的偏倚风险和混杂风险高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The impact of surgeon and hospital volume on outcomes after radical prostatectomy (RP) for localised prostate cancer (PCa) remains unknown. OBJECTIVE: To perform a systematic review on the association between surgeon or hospital volume and oncological and nononcological outcomes following RP for PCa. EVIDENCE ACQUISITION: Medline, Medline In-Process, Embase, and the Cochrane Central Register of Controlled Trials were searched. All comparative studies for nonmetastatic PCa patients treated with RP published between January 1990 and May 2020 were included. For inclusion, studies had to compare hospital or surgeon volume, defined as caseload per unit time. Main outcomes included oncological (including prostate-specific antigen persistence, positive surgical margin [PSM], biochemical recurrence, local and distant recurrence, and cancer-specific and overall survival) and nononcological (perioperative complications including need for blood transfusion, conversion to open procedure and within 90-d death, and continence and erectile function) outcomes. Risk of bias (RoB) and confounding assessments were undertaken. Both a narrative and a quantitative synthesis were planned if the data allowed. EVIDENCE SYNTHESIS: Sixty retrospective comparative studies were included. Generally, increasing surgeon and hospital volumes were associated with lower rates of mortality, PSM, adjuvant or salvage therapies, and perioperative complications. Combining group size cut-offs as used in the included studies, the median threshold for hospital volume at which outcomes start to diverge is 86 (interquartile range [IQR] 35-100) cases per year. In addition, above this threshold, the higher the caseload, the better the outcomes, especially for PSM. RoB and confounding were high for most domains. CONCLUSIONS: Higher surgeon and hospital volumes for RP are associated with lower rates of PSMs, adjuvant or salvage therapies, and perioperative complications. This association becomes apparent from a caseload of >86 (IQR 35-100) per year and may further improve hereafter. Both high- and low-volume centres should measure their outcomes, make them publicly available, and improve their quality of care if needed. PATIENT SUMMARY: We reviewed the literature to determine whether the number of prostate cancer operations (radical prostatectomy) performed in a hospital affects the outcomes of surgery. We found that, overall, hospitals with a higher number of operations per year have better outcomes in terms of cancer recurrence and complications during or after hospitalisation. However, it must be noted that surgeons working in hospitals with lower annual operations can still achieve similar or even better outcomes. Therefore, making hospital's outcome data publicly available should be promoted internationally, so that patients can make an informed decision where they want to be treated.
引用
- Van den Broeck T, Oprea-Lager D, Moris L, et al. A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. Eur Urol. 2021. PMID: 33962808. doi:10.1016/j.eururo.2021.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。